76 related articles for article (PubMed ID: 15158342)
1. Inhibition of hepatitis C virus NS3-mediated cell transformation by recombinant intracellular antibodies.
Zemel R; Berdichevsky Y; Bachmatov L; Benhar I; Tur-Kaspa R
J Hepatol; 2004 Jun; 40(6):1000-7. PubMed ID: 15158342
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of hepatitis C virus RNA replicons by peptide aptamers.
Trahtenherts A; Gal-Tanamy M; Zemel R; Bachmatov L; Loewenstein S; Tur-Kaspa R; Benhar I
Antiviral Res; 2008 Mar; 77(3):195-205. PubMed ID: 18243349
[TBL] [Abstract][Full Text] [Related]
3. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.
Gal-Tanamy M; Zemel R; Berdichevsky Y; Bachmatov L; Tur-Kaspa R; Benhar I
J Mol Biol; 2005 Apr; 347(5):991-1003. PubMed ID: 15784258
[TBL] [Abstract][Full Text] [Related]
4. Isolation of scFvs that inhibit the NS3 protease of hepatitis C virus by a combination of phage display and a bacterial genetic screen.
Nahary L; Trahtenherts A; Benhar I
Methods Mol Biol; 2009; 562():115-32. PubMed ID: 19554291
[TBL] [Abstract][Full Text] [Related]
5. Molecular cloning, sequencing and expression of core and NS3 fragments of HCV from patients with HCV infection.
Tan DM; Hu GL; Arima T; Zhang Z; Nanba T; Hatanaka T
Chin Med J (Engl); 1993 Jul; 106(7):522-6. PubMed ID: 8243124
[TBL] [Abstract][Full Text] [Related]
6. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Dahl G; Sandström A; Akerblom E; Danielson UH
Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
[TBL] [Abstract][Full Text] [Related]
7. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.
Gal-Tanamy M; Zemel R; Bachmatov L; Jangra RK; Shapira A; Villanueva RA; Yi M; Lemon SM; Benhar I; Tur-Kaspa R
Antiviral Res; 2010 Oct; 88(1):95-106. PubMed ID: 20705106
[TBL] [Abstract][Full Text] [Related]
9. Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV.
Akhavan S; Schnuriger A; Lebray P; Benhamou Y; Poynard T; Thibault V
J Infect Dis; 2009 Aug; 200(4):524-7. PubMed ID: 19604114
[TBL] [Abstract][Full Text] [Related]
10. [Inducible expression of non-structural protein 3 of hepatitis C virus in E. coli].
Cheng J; Zhong Y; Liu Y; Dong J; Yang J; Yang S
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Mar; 16(1):85-7. PubMed ID: 11986756
[TBL] [Abstract][Full Text] [Related]
11. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
12. Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation.
Mello IM; Thumann C; Schvoerer E; Soulier E; Pinho JR; Silvestre DA; Queiroz AT; Wolf P; Baumert TF; Keller FS; Pereira CA
J Viral Hepat; 2009 Oct; 16(10):732-7. PubMed ID: 19486468
[TBL] [Abstract][Full Text] [Related]
13. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
Franco S; Clotet B; Martínez MA
Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
[TBL] [Abstract][Full Text] [Related]
14. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4(+) Th1 cell responses in vivo.
Gao M; Wang HP; Wang YN; Zhou Y; Wang QL
Vaccine; 2006 Jun; 24(26):5491-7. PubMed ID: 16725235
[TBL] [Abstract][Full Text] [Related]
15. [The preparation of human single chain Fv antibody specifically against hepatitis C virus NS3 antigen and its application in immunohistochemistry].
Zhong Y; Wang S; Zhao J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Jun; 15(2):186-8. PubMed ID: 11436657
[TBL] [Abstract][Full Text] [Related]
16. [Construction of point mutation plasmids expressing HCV NS3/4A with different secondary structures at amino-terminal and their expressions in Huh 7 cells].
Wang XP; Li FJ; Motoko NF; Kikumi K; Hotta H
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):720-3. PubMed ID: 19403405
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
Hamill P; Jean F
Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
[TBL] [Abstract][Full Text] [Related]
18. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients.
Vallet S; Gouriou S; Nousbaum JB; Legrand-Quillien MC; Goudeau A; Picard B
J Med Virol; 2005 Apr; 75(4):528-37. PubMed ID: 15714495
[TBL] [Abstract][Full Text] [Related]
19. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.
Lei YF; Yin W; Yang J; Lv X; Wei SH; An QX; Hu XB; Xu ZK
Acta Virol; 2008; 52(3):133-41. PubMed ID: 18999887
[TBL] [Abstract][Full Text] [Related]
20. Complex formation between hepatitis C virus NS2 and NS3 proteins.
Kiiver K; Merits A; Ustav M; Zusinaite E
Virus Res; 2006 May; 117(2):264-72. PubMed ID: 16324764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
